Antibodies News and Research

RSS

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.

1 Nov 2021

New genetic epidemiology tool provides detailed information about viruses, coinfections

With mask wearing and social distancing on the decline and the cold and flu season upon us, researchers have developed a viral panel that enables the simultaneous testing for SARS-CoV-2 along with numerous common respiratory viruses, that tells us whether other viruses also are at play in patients hard hit by COVID.

1 Nov 2021

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

The magnitude of cross-reactive antibodies correlated well with responses to the SARS-CoV-2 spike protein and the S2 subdomain.

1 Nov 2021

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

A cohort study found that antibodies to the SARS-CoV-2 spike protein and neutralizing antibodies remain relatively stable 8-11 months post-infection.

1 Nov 2021

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

1 Nov 2021

Potential link between SARS-CoV-2 infection and secondary occurrence of anti-NMDAR encephalitis

Scientists explore the link between SARS-CoV-2 infection and anti-NMDAR encephalitis.

1 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

BNT162b2 mRNA COVID-19 vaccine effectiveness amongst Italian healthcare workers

A new study has been published in Vaccines that evaluated the effectiveness of Cominarty against documented SARS-CoV-2 infection and symptomatic diseases in the medium to long term.

1 Nov 2021

Structural and molecular contributions to understanding antibody recognition of pathogenic viruses

A new review discusses how molecular and structural biology have contributed to our understanding of antibody recognition of HIV-1, SARS-CoV-2, and Zika.

1 Nov 2021

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

A new study develops an inhaled microfluidic microsphere with a genetically engineered membrane from the ACE2 receptor-overexpressing cells and macrophages.

1 Nov 2021

Study suggests increased pediatric COVID-19 hospitalizations related to increased Delta variant incidence

The current study compares the severity of the illness in children infected by the wild-type strain compared with the VOC now prevalent in terms of outcomes in this age group.

1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

A new study explores the role of new SARS-CoV-2 variants in sustaining the pandemic in South Africa.

31 Oct 2021

Clinical assay validation for SARS-CoV-2 sequencing using Swift Biosciences amplicon panel

The current study used the guidelines of the FDA to validate the one-tube SARS-CoV-2 Swift Normalase Amplicon Panel Version 2.0 from Swift Biosciences.

31 Oct 2021

New Canadian serology solution for SARS-CoV-2 infections and vaccination

A new study developed a “Made-in-Canada” solution for enabling scalable and reproducible SARS-CoV-2 serology.

31 Oct 2021

Harnessing the genetics of hookworms to develop next generation of PPE for combat troops

Researchers at Washington University School of Medicine in St. Louis have received a grant to develop the next generation of personal protective equipment (PPE) for combat troops.

30 Oct 2021

Researchers explore whether salivary glands infected with SARS-CoV-2 can diminish long-term immunity

University of Utah Health scientists are leading an effort to determine if salivary glands infected with the virus that causes COVID-19 could diminish a person’s long-term immunity to the disease after being immunized or after recovering from the illness.

30 Oct 2021

Researchers decipher when and why T cells become non-responsive to immunotherapy

Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are "exhausted" and have stopped working.

30 Oct 2021

Study: mRNA vaccines associated with more immunity than prior COVID-19 infection

A nationwide study from the Centers for Disease Control and Prevention shows that mRNA COVID-19 vaccines are associated with significantly more immunity than a prior COVID-19 infection.

29 Oct 2021

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision.

29 Oct 2021

Antibodies News and Research

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

New genetic epidemiology tool provides detailed information about viruses, coinfections

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

Potential link between SARS-CoV-2 infection and secondary occurrence of anti-NMDAR encephalitis

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

BNT162b2 mRNA COVID-19 vaccine effectiveness amongst Italian healthcare workers

Structural and molecular contributions to understanding antibody recognition of pathogenic viruses

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

Study suggests increased pediatric COVID-19 hospitalizations related to increased Delta variant incidence

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

Clinical assay validation for SARS-CoV-2 sequencing using Swift Biosciences amplicon panel

New Canadian serology solution for SARS-CoV-2 infections and vaccination

Harnessing the genetics of hookworms to develop next generation of PPE for combat troops

Researchers explore whether salivary glands infected with SARS-CoV-2 can diminish long-term immunity

Researchers decipher when and why T cells become non-responsive to immunotherapy

Study: mRNA vaccines associated with more immunity than prior COVID-19 infection

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

How to make hybridoma-based antibody discovery more efficient eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News